Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  binimetinib
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2114, NCI-2013-01329, NCT01781572
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
Binimetinib in Treating Patients with Relapsed, Refractory, or Poor Prognosis Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0116, NCI-2014-01518, NCT02089230
Nilotinib and Binimetinib in Treating Patients with Refractory or Advanced Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0128, NCI-2015-00044, CAMN107AUS41T, NCT02225574
Intermittent LGX818 and MEK162 in Treating Patients with Metastatic Melanoma Who Have BRAFV600 Mutations
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-000616, NCI-2014-01971, NCT02263898
MEK inhibitor MEK162 and Erlotinib Hydrochloride in Treating Patients with Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17361, NCI-2013-02386, CMEK162XUS04T, MCC 17361, NCT01859026
Binimetinib, Idarubicin, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: HEMAML0030, NCI-2014-00169, NCT02049801
Binimetinib in Combination with Docetaxel in Treating Patients with Previously Treated, Stage IV Non-small Cell Lung Cancer
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-001595, NCI-2015-00618, Garon MEK162 NSCLC, NCI-2015-00440, NCT02451865
Combination Chemotherapy and Binimetinib in Treating Patients with KRAS Positive Metastatic Colorectal Cancers
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI87144, NCI-2016-00331, CMEK162AUS12T, MEK162/FOLFIRI, NCT02613650
Start Over